{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:45:50Z","timestamp":1787618750883,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"abstract":"\n Objective<\/jats:title>\n \n To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by\n 68<\/jats:sup>\n Ga DOTATATE PET\/CT imaging.\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A retrospective analysis of a prospective database of patients with NETs.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Fasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP), and 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were measured. Correlation between biomarkers and total\n 68<\/jats:sup>\n Ga-DOTATATE-avid tumor volume (TV) was analyzed.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The analysis included 232 patients. In patients with pancreatic NETs (\n n<\/jats:italic>\n \u2009=\u2009112),\n 68<\/jats:sup>\n Ga-DOTATATE TV correlated with CgA (\n r<\/jats:italic>\n \u2009=\u20090.6,\n P<\/jats:italic>\n \u2009=\u20090.001, Spearman). In patients with multiple endocrine neoplasia type 1 (\n n<\/jats:italic>\n \u2009=\u200939),\n 68<\/jats:sup>\n Ga-DOTATATE TV correlated with glucagon (\n r<\/jats:italic>\n \u2009=\u20090.5,\n P<\/jats:italic>\n \u2009=\u20090.01) and PP levels (\n r<\/jats:italic>\n \u2009=\u20090.5,\n P<\/jats:italic>\n \u2009=\u20090.049). In patients with von Hippel\u2013Lindau (\n n<\/jats:italic>\n \u2009=\u200924), plasma VIP (\n r<\/jats:italic>\n \u2009=\u20090.5,\n P<\/jats:italic>\n \u2009=\u20090.02) and PP levels (\n r<\/jats:italic>\n \u2009=\u20090.7,\n P<\/jats:italic>\n \u2009<\u20090.001) correlated with\n 68<\/jats:sup>\n Ga-DOTATATE TV. In patients with small intestine NET (SINET,\n n<\/jats:italic>\n \u2009=\u200974),\n 68<\/jats:sup>\n Ga-DOTATATE TV correlated with CgA (\n r<\/jats:italic>\n \u2009=\u20090.5,\n P<\/jats:italic>\n \u2009=\u20090.02) and 5-HIAA levels (\n r<\/jats:italic>\n \u2009=\u20090.7,\n P<\/jats:italic>\n \u2009<\u20090.001), with 5-HIAA \u22658.1\u2009mg\/24\u2009h associated with metastatic disease with high positive (81.8%) and negative (85.7%) predictive values (\n P<\/jats:italic>\n \u2009=\u20090.001).\n 68<\/jats:sup>\n Ga-DOTATATE TV in patients with NET of unknown primary (\n n<\/jats:italic>\n \u2009=\u200916) and those with NET of other primary location (\n n<\/jats:italic>\n \u2009=\u200930) correlated with 5-HIAA levels (\n r<\/jats:italic>\n \u2009=\u20090.8,\n P<\/jats:italic>\n \u2009=\u20090.002 and\n r<\/jats:italic>\n \u2009=\u20090.7,\n P<\/jats:italic>\n \u2009=\u20090.02 respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our data supports the use of specific NET biomarkers based on the site of the primary NET and the presence of hereditary syndrome-associated NET. High urinary 5-HIAA levels indicate the presence of metastatic disease in patients with SINET.<\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/eje-16-1079","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T20:25:35Z","timestamp":1489436735000},"page":"575-582","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":43,"title":["Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements"],"prefix":"10.1093","volume":"176","author":[{"given":"Amit","family":"Tirosh","sequence":"first","affiliation":[{"name":"1Section on Medical NeuroendocrinologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"2Sackler Faculty of MedicineTel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios Z","family":"Papadakis","sequence":"additional","affiliation":[{"name":"3PET-DepartmentNational Institutes of Health Clinical Center, Bethesda, Maryland, USA"},{"name":"4Institute of Computer Science (ICS)Foundation for Research and Technology Hellas (FORTH), Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Millo","sequence":"additional","affiliation":[{"name":"3PET-DepartmentNational Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira M","family":"Sadowski","sequence":"additional","affiliation":[{"name":"5Endocrine and Thoracic SurgeryUniversity Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Herscovitch","sequence":"additional","affiliation":[{"name":"3PET-DepartmentNational Institutes of Health Clinical Center, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"1Section on Medical NeuroendocrinologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Marx","sequence":"additional","affiliation":[{"name":"1Section on Medical NeuroendocrinologyEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Yang","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Nockel","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Shell","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience","family":"Green","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier M","family":"Keutgen","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"7Department of SurgeryRush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Patel","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electron","family":"Kebebew","sequence":"additional","affiliation":[{"name":"6Endocrine Oncology BranchNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"8Department of SurgeryThe George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2017031317252360000_176.5.575.1","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"2017031317252360000_176.5.575.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.12.005"},{"key":"2017031317252360000_176.5.575.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70362-0"},{"key":"2017031317252360000_176.5.575.4","doi-asserted-by":"publisher","DOI":"10.1159\/000443171"},{"key":"2017031317252360000_176.5.575.5","doi-asserted-by":"publisher","DOI":"10.1159\/000443170"},{"key":"2017031317252360000_176.5.575.6","doi-asserted-by":"publisher","DOI":"10.1159\/000225952"},{"key":"2017031317252360000_176.5.575.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00186-2"},{"key":"2017031317252360000_176.5.575.8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-015-3027-4","article-title":"Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?","volume":"42","author":"Santhanam","year":"2015","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"2017031317252360000_176.5.575.9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2478\/raon-2014-0018","article-title":"Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET\/CT and In-111 DTPA octreotide SPECT\/CT","volume":"48","author":"Schreiter","year":"2014","journal-title":"Radiology and Oncology"},{"key":"2017031317252360000_176.5.575.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0987"},{"key":"2017031317252360000_176.5.575.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.179234"},{"key":"2017031317252360000_176.5.575.12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/MNM.0000000000000522","article-title":"Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET\/CT on the basis of volumetric parameters in neuroendocrine tumors","volume":"37","author":"Abdulrezzak","year":"2016","journal-title":"Nuclear Medicine Communications"},{"key":"2017031317252360000_176.5.575.13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5152\/dir.2015.15304","article-title":"Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC","volume":"22","author":"Cieciera","year":"2016","journal-title":"Diagnostic and Interventional Radiology"},{"key":"2017031317252360000_176.5.575.14","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.3748\/wjg.v22.i30.6817","article-title":"Management of gastric and duodenal neuroendocrine tumors","volume":"22","author":"Sato","year":"2016","journal-title":"World Journal of Gastroenterology"},{"key":"2017031317252360000_176.5.575.15","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ec124e"},{"key":"2017031317252360000_176.5.575.16","doi-asserted-by":"crossref","unstructured":"Roberts RO Aakre JA Cha RH Kremers WK Mielke MM Velgos SN Geda YE Petersent RC. Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE 4\u05d5 Allele. Frontiers in Aging Neuroscience 2015. (doi:10.3389\/fnagi.2015.00172)","DOI":"10.3389\/fnagi.2015.00172"},{"key":"2017031317252360000_176.5.575.17","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1093\/clinchem\/48.11.2049","article-title":"Liquid Chromatographic\u2013Tandem Mass Spectrometric Method for the Determination of 5-Hydroxyindole-3-acetic Acid in Urine","volume":"48","author":"Kroll","year":"2002","journal-title":"Clinical Chemistry"},{"key":"2017031317252360000_176.5.575.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2014.04.014"},{"key":"2017031317252360000_176.5.575.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158626"},{"key":"2017031317252360000_176.5.575.20","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100459"},{"key":"2017031317252360000_176.5.575.21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MEG.0000000000000332","article-title":"The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases","volume":"27","author":"Han","year":"2015","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"2017031317252360000_176.5.575.22","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198708000-00001"},{"key":"2017031317252360000_176.5.575.23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11226"},{"key":"2017031317252360000_176.5.575.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.165803"},{"key":"2017031317252360000_176.5.575.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.166017"},{"key":"2017031317252360000_176.5.575.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.beem.2016.01.003","article-title":"Gastroenteropancreatic neuroendocrine tumours (GEP-NET) \u2013 imaging and staging","volume":"30","author":"Baumann","year":"2016","journal-title":"Best Practice and Research Clinical Endocrinology and Metabolism"},{"key":"2017031317252360000_176.5.575.27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers4010141","article-title":"Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review","volume":"4","author":"N\u00f6lting","year":"2012","journal-title":"Cancers"},{"key":"2017031317252360000_176.5.575.28","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2010.10"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/176\/5\/575.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1530\/EJE-16-1079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:10:27Z","timestamp":1676373027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/176\/5\/575\/6655119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/eje-16-1079","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}